Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Jaklic
Janez Jaklic, Muenchen DE
| Patent application number | Description | Published |
|---|---|---|
| 20100125822 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODCUT FOR IMPLEMENTING INTERACTIVE CROSS-DOMAIN PACKAGE DRIVEN I/O PLANNING AND PLACEMENT OPTIMIZATION - Disclosed are a method, a system, and a computer program product for implementing interactive cross-domain package driven I/O planning and placement optimization of an electronic circuit design. In some embodiments, the method identifies an object on a first EDA tool session, determines a drop location for the first object based on a tentative location in the first EDA tool session, places the first object at the drop location, and adjusts the drop location via a second EDA tool session, performs placement or routing of a portion of the design. The method or the system further comprises placing a corresponding first object in the second EDA tool session, initiating the second EDA tool session object move in the first EDA tool session, determining whether a constraint is satisfied. | 05-20-2010 |
Miha T. Jaklic, Ljubljana SI
| Patent application number | Description | Published |
|---|---|---|
| 20120087953 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE PHARMACEUTICAL INGREDIENT COMPRISING SULPHONYLUREA MOIETY WITH EXCELLENT DISSOLUTION PROPERTIES - The present invention provides a pharmaceutical composition comprising at least one active pharmaceutical ingredient comprising sulphonylurea moiety, wherein the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is intimately mixed with a basic agent. The weight ratio of the basic agent and the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is from 2.5:1 to 50:1, preferably from 2.5:1 to 25:1, more preferably from 3.5:1 to 15:1, yet more preferably from 3.5:1 to 10:1. The pharmaceutical composition can be obtained by simply mixing active pharmaceutical ingredient comprising sulphonylurea moiety and the basic agent in the aforementioned weight ratio, optionally in the presence of the granulation liquid. Alternatively, the pharmaceutical composition can be obtained by at least partially or fully dissolving the compounds in the granulation liquid or solvent, and at least partly precipitating them. The invention provides improved dissolution properties of the active pharmaceutical ingredient comprising sulphonylurea moiety. | 04-12-2012 |
| 20120088774 | ACTIVE PHARMACEUTICAL INGREDIENT ADSORBED ON SOLID SUPPORT - The present invention belongs to the field of pharmaceutical industry and relates to dosage forms comprising active pharmaceutical ingredients (API) such as tadalafil, simvastatin, fenofibrate and lovastatin that are practically insoluble in water, adsorbed on a carrier. Furthermore it relates to an adsorbate comprising API being practically insoluble in water and to a process for the preparation of said adsorbate with non-polar solvent (s) such as chlorinated hydrocarbon, diisopropylethes and hexane. Furthermore the invention relates to a process for the preparation of the dosage form, as well as to the use of the adsorbate for the preparation of the dosage form. Moreover it relates to the dosage form for use in the treatment of erectile dysfunction, human immunodeficiency virus (HIV) infections and/or Acquired Immune Deficiency Syndrome (AIDS). | 04-12-2012 |
Miha Tomaz Jaklic, Ljubljana SI
| Patent application number | Description | Published |
|---|---|---|
| 20100120868 | Process For Preparing Solid Dosage Forms of Rosiglitazone Maleate - The invention relates to a process for preparing a solid pharmaceutical composition rosiglitazone maleate, comprising the step of adsorption of rosiglitazone maleate onto carrier particles (C) during a dry mixing process. | 05-13-2010 |
| 20110008439 | DULOXETIN COMPOSITION - The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt. | 01-13-2011 |
Miha Tomaz Jaklic, Dol Pri Ljubljani SI
| Patent application number | Description | Published |
|---|---|---|
| 20090093499 | Pharmaceutical composition - A chemically stable formulation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically-acceptable salt thereof for oral use, such as tablets, capsules, powders, granules has been developed using the substances which stabilize against formation of degradation products: lactone and oxidation product. | 04-09-2009 |